Fujifilm Buys Shenandoah Biotechnology
Fujifilm Irvine Scientific, part of Japan’s Fujifilm Holdings, will acquire Shenandoah Biotechnology, a US-based, privately held manufacturer of recombinant proteins. Financial terms of the deal, which is expected to close later this month, were not disclosed.
Based in Warminster, Pennsylvania, Shenandoah Biotechnology recently launched its CTG grades of cytokines and growth factors, which are important drivers of cellular processes such as cell proliferation, growth, differentiation and cell signaling.
"Shenandoah Biotechnology’s portfolio of recombinant proteins complement our advanced cell culture solutions and expertise in bioprocessing, providing our collective customers a single point of access for their life science research, discovery, and cell and gene therapy needs,” said Yutaka Yamaguchi, chairman and CEO of Fujifilm Irvine Scientific. He added that the acquisition will be an important step toward achieving a sales target of 100 billion yen – or about $850 million – in Fujifilm’s Life Sciences business by 2025.
Last December, Fujifilm Irvine Scientific announced the opening of a third manufacturing facility, complementing plants in California, USA, and Tokyo, Japan. The new facility is located in Tilburg, the Netherlands, and manufactures dry powder and liquid media, buffers and water for injection, acting as a hub for both European and global markets.
The plant increases the company’s annual production capacity by approximately 320,000 kg of dry powder media and by about 470,000 liters of liquids, with the capability to expand rapidly.
Author: Elaine Burridge, Freelance Journalist
